AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01302145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT00621504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
Study NCT00621504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
Study NCT01577485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics in an pastille
Description: Test group
Study NCT01577485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control pastille
Description: Control group
Study NCT02013843 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community-based treatment of overweight and obesity
Description: Community based treatment of overweight and obese children using the Holbaek-method.
Study NCT01935050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Cognitive-Behavioral Self-Help
Description: Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
Study NCT01354483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cell
Study NCT01354483 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 30mg/kg i.v. methylprednisolone
Study NCT01354483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate Tablet
Description: 6 weeks
Study NCT03590509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Program
Description: A telemedicine platform (Zoom) will be added to comprehensive care (CC) to be used by the CC providers to make observations in the home to augment care, help address acute problems remotely at any hour, better coordinate care with healthcare personnel, and thereby reduce clinic visits, ED visits, and hospitalizations. Home visits\* will be conducted by a nurse home visitor whenever considered likely to be beneficial for any of the CMC and at least once by the assigned CC provider immediately following enrollment of children with chronic respiratory failure requiring mechanical ventilation at home.~\*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented
Study NCT03590509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Comprehensive Care
Description: Comprehensive care (CC) provided in an enhanced medical home to assure effective care at any hour for or children with medical complexity
Study NCT00428649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 µg selenium
Description: 20 µg selenium as selenomethionine
Study NCT00655174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Description: Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
Study NCT00428649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 µg selenium
Description: 40 µg selenium as selenomethionine
Study NCT00428649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 60 µg selenium
Description: 60 µg selenium as selenomethionine
Study NCT00428649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 80 µg selenium
Description: 80 µg selenium as selenomethionine
Study NCT00428649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100 µg selenium
Description: 100 µg selenium as selenomethionine
Study NCT00428649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 120 µg selenium
Description: 120 µg selenium as selenomethionine
Study NCT00428649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00655174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
Study NCT00655174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
Study NCT03711240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5mg/kg iv day 1 every 2 weeks
Study NCT03711240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study NCT03711240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150mg/m2 1.5-hour iv infusion, day 1 every 2 weeks
Study NCT03711240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m2 2-hour iv infusion, day 1 every 2 weeks
Study NCT03711240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
Study NCT03094507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivicay
Description: 50 mg once daily
Study NCT03094507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezolsta
Description: darunavir 800 mg/cobicistat 150 mg once daily
Study NCT03159312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity based on a moderate exercise program
Description: Physical exercise program begins with a 2-week adaptation stage, climbs onto the treadmill (HP Cosmos®). The programming of the tape will be done initially with an intensity of 40% of its FCdRes obtained from the formula of Karvonen after performing the 6-minute walk test, you will have to maintain that intensity for 15 min, the patient is evaluated with the Borg scale and oxygen saturation permanently.After two weeks of adaptation, the HRdRes becomes to be calculated, 59% of said frequency will be modified until the exercise program is completed.The training is 30 minutes in the tradmill machine.The work of muscle strengthening of biceps, triceps, deltoids and pectorals, will be progressive in intensity and number of repetitions, determined by the evaluation of 1 Rmax. The start of work with weights is 40% of the Rmax, it will be modified monthly from 40% to 75%. Cycloergometer training (Monark ®) is without load for 15 minutes.
Study NCT00272038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 150mg QD
Study NCT04590846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constipation Health Education Intervention Course
Description: The 4-weeks health education includes three dimensions. The first is Causes and Hazards of Constipation. The second is Constipation Symptoms and Criteria. The third is Constipation Treatment Strategies and Prevention.~Health education leaflets with 3 to 5 test questions in the weekly are distributed once a week, students will bring them back to parents, and parents need to complete the answers and sign after reading them.
Study NCT06471881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two mandibular implants
Description: Rehabilitation with two mandibular implants and a mandibular implant overdenture supported by a computer-aided design bar
Study NCT03072693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based remote heart failure management
Description: For patients randomized to Group 1, the home-based remote heart failure management system will be connected via the internet for active intervention. In Group 2 patients, the system will not be activated although all data will continue to be stored and reviewed at clinic visits. For patients in Group 1, clinically-assigned targets and alert thresholds of individual physiological parameters including blood pressure, pulse rate, and body weight will be decided before discharge and at entry into the three management modes. Site investigators will review individual patient physiological parameters upon clinic visits, and treatment can be initiated through instant communication (electronic communication and/or phone).
Study NCT03072693 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Home-based physiological parameter recording only
Description: For patients randomized to Group 2, the home-based remote heart failure management system will continuously record and store patients information to be reviewed at clinic visits but not connected to internet. Site investigators will review individual patient physiological parameters upon clinic visits, and no treatment will be initiated through instant communication.
Study NCT00772629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study NCT03457675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S DBS implant for OCD
Description: DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna
Study NCT03457675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Month Blinded Discontinuation Period
Description: The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline.
Study NCT04590846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Course
Description: General courses about health issues according to the curriculum of each primary school.
Study NCT04590846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Course
Description: General courses about health issues according to the curriculum of each primary school.
Study NCT04525716 — intervention group
Intervention type: OTHER
Intervention: COVID-19 infection status
Description: We will compare patients with/without confirmed COVID-19 infection
Study NCT03879564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
Study NCT03879564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
Study NCT00552747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: fenofibrate 160 mg capsules qd
Study NCT00552747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules placebo
Study NCT01587898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Tablet
Study NCT02397928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L device
Description: Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
Study NCT02397928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
Study NCT01587898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study NCT02080819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa 400/100 BID
Description: Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance.
Study NCT02080819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levodopa/carbidopa 400/100 BID
Description: Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance.
Study NCT02498171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine with fentanyl
Description: Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery
Study NCT02498171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine with bupivacaine
Description: Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery
Study NCT01788215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 200mg/day in divided doses of 100mg twice daily
Study NCT01788215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 1 pill twice a day
Study NCT02397928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
Study NCT01897246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corrective osteotomy with computer-assisted pre-operative planning
Description: The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
Study NCT01897246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corrective osteotomy with conventional preoperative planning
Description: The corrective osteotomy will be planned with conventional preoperative planning.
Study NCT00477126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GPO ritonavir versus Norvir
Description: RTV generic compared to reference drugs (Norvir, Abbott)
Study NCT02405338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1/PRAME vaccination
Study NCT02871037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Single or repeated, escalating dose of PF-05221304
Study NCT01960322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemetric
Description: A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
Study NCT02549339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 gel
Study NCT02549339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study NCT01014845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis E vaccine
Description: Intramuscularly given at 0, 1, 6m for three doses.
Study NCT02871037 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single or repeated dose of placebo
Study NCT02871037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single or repeated dose of placebo
Study NCT02340871 — intervention group
Intervention type: GENETIC
Intervention: Genetic testing
Description: Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
Study NCT02527772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin+Gemcitabine
Description: Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
Study NCT02527772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4
Description: Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
Study NCT00612105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine
Description: 150mg/day up to 900mg/day
Study NCT00612105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study NCT03228329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fluid boluses
Description: fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
Study NCT01651962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Study NCT01651962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT01651962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Study NCT01846767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose breath test
Description: Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton \& Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
Study NCT02778113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: Administered intranasally.
Study NCT01014845 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Intramuscularly given at 0, 1, 6m for three doses.
Study NCT02276092 — intervention group
Intervention type: OTHER
Intervention: antimicrobial stewardship
Description: A member of the antimicrobial stewardship program will prospectively review the patient's medical record and make recommendations to the most responsible physician in the care of that patient
Study NCT01137240 — intervention group
Intervention type: PROCEDURE
Intervention: gastric emptying scan
Description: subjects will eat a solid meal (scrambled eggs, etc) or drink liquid (water or juice) mixed with approximately 0.5 millicuries of radioactive material. A scanner/external gamma camera will be placed over the subject's stomach at 15 minute intervals for a duration of 90 minutes (monitoring the amount of radioactivity in the stomach). As the radioactively-labeled food empties from the stomach, the amount of radioactivity in the stomach decreases. The rate at which the radioactivity leaves the stomach reflects the rate at which food is emptying from the stomach. The radioisotope has a half life of approximately. 6 hours and is totally eliminated from the body within 24 hours.~In subjects with gastroparesis, the food and the attached radioactive material remain in the stomach longer than normal (usually hours) before emptying into the small intestine. As a result, the scanner continues to show radioactivity in the area of the stomach for hours after the test meal.
Study NCT02841059 — intervention group
Intervention type: PROCEDURE
Intervention: LSH
Description: laparoscopic subtotal hysterectomy: LSH
Study NCT02841059 — intervention group
Intervention type: PROCEDURE
Intervention: CLSH
Description: laparoscopic cervical ligament sparing hysterectomy: CLSH
Study NCT02841059 — intervention group
Intervention type: PROCEDURE
Intervention: LAVH
Description: laparoscopic assisted vaginal hysterectomy: LAVH